1. Norway Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nykode Therapeutics ASA

Nykode Therapeutics ASA

0.45
USD
+0.03
(+6.80%)
-0.06EPS
104.92MMarket Cap
Nov 25Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.77
0.12
0.02
0.04
0.03
- -
- -
Basic EPS, GAAP
- -
- -
-0.05
0.54
-0.03
-0.15
-0.12
-0.12
-0.04
-0.06
Free Cash Flow per Basic Share
- -
- -
-0.04
0.64
- -
-0.08
-0.33
-0.16
-0.09
-0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.1
- -
Book Value per Share
0.01
0.01
0.1
0.63
0.67
0.53
0.52
0.42
0.28
0.25
Tangible Book Value per Share
0.01
0.01
0.1
0.63
0.67
0.53
0.52
0.42
0.28
0.25
Basic Weighted Avg Shares
284
284
284
280
286
290
301
327
327
384
Sales/Revenue/Turnover
- -
- -
- -
215
34
7
13
9
- -
- -
Operating Margin (%)
-6,986.71
-51,104.16
- -
82.91
-31.73
-741.57
-450.18
-556.9
- -
- -
Depreciation Expense
- -
- -
- -
- -
1
2
2
2
2
2
Net Income, GAAP
- -
-1
-14
150
-9
-43
-35
-39
-12
-23
Effective Tax Rate (%)
- -
- -
- -
17.21
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-6,452.47
-49,517.89
- -
69.66
-27.72
-596.3
-272.47
-447.3
- -
- -
Working Capital
3
2
29
216
224
173
145
108
56
44
LT Debt
- -
- -
- -
- -
6
4
4
2
1
1
Total Equity
3
2
28
179
194
157
171
136
92
80
Return on Invested Capital (%)
- -
- -
- -
141.47
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
144.85
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-35.52
-93.23
145.07
-5.05
-24.35
-21.42
-25.25
-10.75
-25.07

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
327
327
327
Market Capitalization
51
124
105

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
62
55
48
Cash, Cash Equivalents & STI
60
51
45
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
4
4
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-10.96%
-32.8%
Free Cash Flow
- -
-1,639.36%
-42.5%
Net Income, GAAP
- -
34.39%
-68.47%
Sales/Revenue/Turnover
- -
-43.17%
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
7
9
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.03
-0.03
-0.02
-0.12
2025
- -
- -
-0.01
-0.02
-0.04
2026
-0.01
-0.02
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.1
- -
- -
0.1
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michael Thyrring Engsig
Full Time Employees
59
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Oslo Research Park Oslo PS Norway 0349
IPO Date
Jun 16, 2022
Website
nykode.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nykode Therapeutics ASA (OSE: NYKD) is an Oslo-based clinical-stage biopharmaceutical company founded in 2006 that develops novel immunotherapies and vaccines based on its proprietary Vaccibody technology platform, which targets antigens to antigen-presenting cells to induce rapid, strong and long-lasting immune responses for treating cancers and infectious diseases. The company's lead wholly owned candidate, VB10.16, is an off-the-shelf therapeutic cancer immunotherapy in development for human papillomavirus type 16 (HPV16)-positive cancers including cervical, head and neck, and anal cancers; VB10.NEO is a proprietary individualized neoantigen immunotherapy in Phase 1b trials for locally advanced and metastatic solid tumors; additional programs target autoimmune diseases and infectious diseases through modular vaccine designs. Nykode Therapeutics operates primarily from its headquarters at Gaustadalléen 21 in Oslo, Norway, with a global development focus supported by clinical trials in Europe and the United States. Recent developments include the May 2024 expansion of its clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.) for a Phase 2 trial combining VB10.16 with KEYTRUDA (pembrolizumab) in HPV16-positive locally advanced cervical cancer patients undergoing chemoradiotherapy; ongoing discussions with Regeneron regarding a 2021 multi-target partnership covering three cancer vaccine and two infectious disease vaccine programs following preclinical asset adjustments; completion of a Roche collaboration Phase 2 trial in November 2023 evaluating VB10.16 with atezolizumab (Tecentriq) in recurrent or metastatic cervical cancer; and uplisting to the main list of the Oslo Stock Exchange to enhance visibility and access to capital markets.